Accelerate Diagnostics, Inc. (AXDX): Price and Financial Metrics

Accelerate Diagnostics, Inc. (AXDX): $0.70

0.03 (+3.73%)

POWR Rating

Component Grades








Add AXDX to Watchlist
Sign Up

AXDX Price/Volume Stats

Current price $0.70 52-week high $3.74
Prev. close $0.68 52-week low $0.45
Day low $0.68 Volume 148,845
Day high $0.71 Avg. volume 274,616
50-day MA $0.71 Dividend yield N/A
200-day MA $0.99 Market Cap 69.90M

AXDX Stock Price Chart Interactive Chart >


  • AXDX scores best on the Growth dimension, with a Growth rank ahead of 73.63% of US stocks.
  • AXDX's strongest trending metric is Sentiment; it's been moving down over the last 179 days.
  • AXDX's current lowest rank is in the Momentum metric (where it is better than 6.83% of US stocks).

AXDX Stock Summary

  • ACCELERATE DIAGNOSTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 6.52% of US listed stocks.
  • AXDX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 4.94% of US stocks.
  • In terms of volatility of its share price, AXDX is more volatile than 92.11% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to ACCELERATE DIAGNOSTICS INC, a group of peers worth examining would be CHRS, GTHX, ASTC, WB, and OCUL.
  • AXDX's SEC filings can be seen here. And to visit ACCELERATE DIAGNOSTICS INC's official web site, go to

AXDX Valuation Summary

  • AXDX's EV/EBIT ratio is -2; this is 116.67% lower than that of the median Healthcare stock.
  • AXDX's price/earnings ratio has moved up 29 over the prior 243 months.

Below are key valuation metrics over time for AXDX.

Stock Date P/S P/B P/E EV/EBIT
AXDX 2023-05-23 5.8 -1.9 -1.1 -2
AXDX 2023-05-22 5.9 -1.9 -1.1 -2
AXDX 2023-05-19 5.9 -1.9 -1.1 -2
AXDX 2023-05-18 5.8 -1.9 -1.1 -2
AXDX 2023-05-17 6.0 -1.9 -1.1 -2
AXDX 2023-05-16 6.1 -2.0 -1.2 -2

AXDX Growth Metrics

    The 4 year revenue growth rate now stands at 1513.21%.
  • Its year over year revenue growth rate is now at 7.77%.
  • Its 4 year cash and equivalents growth rate is now at 298.17%.
Over the past 15 months, AXDX's revenue has gone up $1,109,000.

The table below shows AXDX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 13.122 -51.125 -70.496
2022-06-30 13.284 -50 -63.777
2022-03-31 12.221 -46.554 -67.648
2021-12-31 11.782 -47.323 -77.702
2021-09-30 11.547 -45.719 -73.811
2021-06-30 12.013 -45.927 -83.582

AXDX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AXDX has a Quality Grade of D, ranking ahead of 23.75% of graded US stocks.
  • AXDX's asset turnover comes in at 0.125 -- ranking 68th of 75 Measuring and Control Equipment stocks.
  • AATC, TMO, and BMI are the stocks whose asset turnover ratios are most correlated with AXDX.

The table below shows AXDX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.125 0.366 -0.333
2021-03-31 0.112 0.379 -0.320
2020-12-31 0.103 0.399 -0.302
2020-09-30 0.097 0.418 -0.316
2020-06-30 0.079 0.458 -0.343
2020-03-31 0.071 0.467 -0.358

AXDX Price Target

For more insight on analysts targets of AXDX, see our AXDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.00 Average Broker Recommendation 1.7 (Moderate Buy)

Accelerate Diagnostics, Inc. (AXDX) Company Bio

Accelerate Diagnostics is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. The company was founded in 1982 and is based in Tucson, Arizona.

AXDX Latest News Stream

Event/Time News Detail
Loading, please wait...

AXDX Latest Social Stream

Loading social stream, please wait...

View Full AXDX Social Stream

Latest AXDX News From Around the Web

Below are the latest news stories about ACCELERATE DIAGNOSTICS INC that investors may wish to consider to help them evaluate AXDX as an investment opportunity.

Q1 2023 Accelerate Diagnostics Inc Earnings Call

Q1 2023 Accelerate Diagnostics Inc Earnings Call

Yahoo | May 12, 2023

Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 0% and 19.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 11, 2023

Accelerate Diagnostics Reports First Quarter 2023 Financial Results

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter for the period ended March 31, 2023.

Yahoo | May 11, 2023

Syneos Health (SYNH) Announces a $7.1 Billion Merger Agreement

Syneos Health (SYNH) is set to become private company following a $7.1 billion merger deal to be acquired by a private investment consortium.

Yahoo | May 11, 2023

Walgreens Boots (WBA) New Alliances Aid Growth, Cost Woe Stays

Intensifying competition in the U.S. pharmacy retail drugstore market compels Walgreens Boots (WBA) to diversify its product offerings through new partnerships.

Yahoo | May 10, 2023

Read More 'AXDX' Stories Here

AXDX Price Returns

1-mo -18.34%
3-mo 38.89%
6-mo -6.67%
1-year 15.07%
3-year -91.62%
5-year -96.57%
YTD -0.85%
2022 -86.48%
2021 -31.13%
2020 -55.15%
2019 46.96%
2018 -56.11%

Continue Researching AXDX

Want to see what other sources are saying about Accelerate Diagnostics Inc's financials and stock price? Try the links below:

Accelerate Diagnostics Inc (AXDX) Stock Price | Nasdaq
Accelerate Diagnostics Inc (AXDX) Stock Quote, History and News - Yahoo Finance
Accelerate Diagnostics Inc (AXDX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!